Danazol
- Generic Name
- Danazol
- Brand Names
- Cyclomen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27NO2
- CAS Number
- 17230-88-5
- Unique Ingredient Identifier
- N29QWW3BUO
- Background
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
- Indication
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
- Associated Conditions
- Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 9
- Registration Number
- NCT04757532
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
- Conditions
- Pulmonary FibrosisTelomere ShorteningTelomere DiseaseDyskeratosis Congenita
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 50
- Registration Number
- NCT04638517
- Locations
- 🇦🇺
Sydney Children's Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04481282
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia
- Conditions
- Low/Intermediate Risk-1 MDS
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT04324060
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
- Conditions
- Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 195
- Registration Number
- NCT04173494
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy
- Conditions
- Telomere Length, Mean LeukocyteTelomere Shortening
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03710356
Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure
- Conditions
- Unexplained Infertility
- Interventions
- Procedure: Pre-treatment endometrial biopsyProcedure: Post-treatment endometrial biopsy
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 38
- Registration Number
- NCT03563664
- Locations
- 🇪🇬
Ain SHams Maternity Hospital, Cairo, Abbaseya, Egypt
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03460808
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Viramal Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03352076
- Locations
- 🇮🇹
Ospedale L. Sacco - Milan-Obgyn Unit, Milan, Italy
Low-Dose Danazol for the Treatment of Telomere Related Diseases
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 40
- Registration Number
- NCT03312400
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.